drugset / Trial / NCT05909995
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Timeline
- Start
- 2023-08-29
- Primary completion
- 2024-09-19
- Completion
- 2024-11-11
Outcome
Outcome not reported
Stopped (Business): “This was a strategic business decision. There were no safety concerns contributing to this decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB 99280 | Unknown | — | — |
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |